{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:11:26Z","timestamp":1794085886761,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87512-8","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:01:24Z","timestamp":1738065684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infection"],"prefix":"10.1038","volume":"15","author":[{"given":"Simone","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Campanile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Flammini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pagotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd H.","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menino O.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"87512_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/clinids\/15.1.63","volume":"15","author":"DW Megran","year":"1992","unstructured":"Megran, D. W. Enterococcal endocarditis. Clin. Infect. Dis. 15, 63\u201371. https:\/\/doi.org\/10.1093\/clinids\/15.1.63 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"87512_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","volume":"39","author":"JL Mainardi","year":"1995","unstructured":"Mainardi, J. L., Gutmann, L., Acar, J. F. & Goldstein, F. W. Synergistic effect of Amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob. Agents Chemother. 39, 1984\u20131987. https:\/\/doi.org\/10.1128\/AAC.39.9.1984 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.7326\/0003-4819-146-8-200704170-00008","volume":"146","author":"J Gavald\u00e0","year":"2007","unstructured":"Gavald\u00e0, J. Brief communication: Treatment of Enterococcus faecalis Endocarditis with Ampicillin plus Ceftriaxone. Ann. Intern. Med. 146, 574. https:\/\/doi.org\/10.7326\/0003-4819-146-8-200704170-00008 (2007).","journal-title":"Ann. Intern. Med."},{"key":"87512_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/cid\/cit052","volume":"56","author":"N Fern\u00e1ndez-Hidalgo","year":"2013","unstructured":"Fern\u00e1ndez-Hidalgo, N. et al. Ampicillin Plus Ceftriaxone is as effective as Ampicillin Plus Gentamicin for treating Enterococcus faecalis infective endocarditis. Clin. Infect. Dis. 56, 1261\u20131268. https:\/\/doi.org\/10.1093\/cid\/cit052 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"87512_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cmi.2019.10.017","volume":"26","author":"D Lebeaux","year":"2020","unstructured":"Lebeaux, D., Fern\u00e1ndez-Hidalgo, N., Pilmis, B., Tattevin, P. & Mainardi, J-L. Aminoglycosides for infective endocarditis: Time to say goodbye? Clin. Microbiol. Infect. 26, 723\u2013728. https:\/\/doi.org\/10.1016\/j.cmi.2019.10.017 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"87512_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/jac\/dkm237","volume":"60","author":"CA Arias","year":"2007","unstructured":"Arias, C. A., Singh, K. V., Panesso, D. & Murray, B. E. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J. Antimicrob. Chemother. 60, 594\u2013598. https:\/\/doi.org\/10.1093\/jac\/dkm237 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"87512_CR7","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1093\/jac\/dkz388","volume":"74","author":"N Peiffer-Smadja","year":"2019","unstructured":"Peiffer-Smadja, N. et al. In vitro bactericidal activity of Amoxicillin combined with different cephalosporins against endocarditis-associated Enterococcus faecalis clinical isolates. J. Antimicrob. Chemother. 74, 3511\u20133514. https:\/\/doi.org\/10.1093\/jac\/dkz388 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"87512_CR8","doi-asserted-by":"publisher","unstructured":"Giuliano, S. et al. Ampicillin and Ceftobiprole Combination for the treatment of Enterococcus faecalis invasive infections: The Times they are A-Changin. Antibiotics (Basel). 12. https:\/\/doi.org\/10.3390\/antibiotics12050879 (2023).","DOI":"10.3390\/antibiotics12050879"},{"key":"87512_CR9","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3390\/microorganisms11122964","volume":"11","author":"PG Cojutti","year":"2023","unstructured":"Cojutti, P. G. et al. Population Pharmacokinetic and Pharmacodynamic Analysis for maximizing the effectiveness of Ceftobiprole in the treatment of severe methicillin-resistant staphylococcal infections. Microorganisms 11, 2964. https:\/\/doi.org\/10.3390\/microorganisms11122964 (2023).","journal-title":"Microorganisms"},{"key":"87512_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-197601040-00004","volume":"1","author":"M Barza","year":"1976","unstructured":"Barza, M. & Weinstein, L. Pharmacokinetics of the penicillins in man. Clin. Pharmacokinet. 1, 297\u2013308. https:\/\/doi.org\/10.2165\/00003088-197601040-00004 (1976).","journal-title":"Clin. Pharmacokinet."},{"key":"87512_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s40262-016-0418-z","volume":"55","author":"A Torres","year":"2016","unstructured":"Torres, A., Mouton, J. W. & Pea, F. Pharmacokinetics and dosing of Ceftobiprole Medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin. Pharmacokinet. 55, 1507\u20131520. https:\/\/doi.org\/10.1007\/s40262-016-0418-z (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"87512_CR12","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1 2023. http:\/\/www.eucast.org (2023)"},{"key":"87512_CR13","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing 33rd ed. CLSI Supplement M100 (Clinical and Laboratory Standards Institute, 2023)."},{"key":"87512_CR14","unstructured":"NCCLS. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Approved Guideline. NCCLS document M26-A [ISBN 1-56238-384-1]. NCCLS 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA (1999)."},{"key":"87512_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1600-0463.2007.apm_630.x","volume":"115","author":"S Stepanovi\u0107","year":"2007","unstructured":"Stepanovi\u0107, S. et al. Quantification of biofilm in microtiter plates: Overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 115, 891\u2013899. https:\/\/doi.org\/10.1111\/j.1600-0463.2007.apm_630.x (2007).","journal-title":"APMIS"},{"key":"87512_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1128\/AAC.17.6.965","volume":"17","author":"DJ Krogstad","year":"1980","unstructured":"Krogstad, D. J. & Pargwette, A. R. Defective killing of enterococci: A common property of antimicrobial agents acting on the cell wall. Antimicrob. Agents Chemother. 17, 965\u2013968. https:\/\/doi.org\/10.1128\/AAC.17.6.965 (1980).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM196603312741304","volume":"274","author":"E Jawetz","year":"1966","unstructured":"Jawetz, E. & Sonne, M. Penicillin-streptomycin treatment of Enterococcal Endocarditis. N. Engl. J. Med. 274, 710\u2013715. https:\/\/doi.org\/10.1056\/NEJM196603312741304 (1966).","journal-title":"N. Engl. J. Med."},{"key":"87512_CR18","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1172\/JCI106758","volume":"50","author":"RC Moellering","year":"1971","unstructured":"Moellering, R. C. & Weinberg, A. N. Studies on antibiotic synergism against enterococci. J. Clin. Invest. 50, 2580\u20132584. https:\/\/doi.org\/10.1172\/JCI106758 (1971).","journal-title":"J. Clin. Invest."},{"key":"87512_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/BF01972497","volume":"10","author":"JTM Meer","year":"1991","unstructured":"Meer, J. T. M. et al. Distribution, antibiotic susceptibility and tolerance of bacterial isolates in culture-positive cases of endocarditis in the Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 10, 728\u2013734. https:\/\/doi.org\/10.1007\/BF01972497 (1991).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"87512_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00392-021-01971-3","volume":"111","author":"M Mirna","year":"2022","unstructured":"Mirna, M., Topf, A., Schmutzler, L., Hoppe, U. C. & Lichtenauer, M. Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials. Clin. Res. Cardiol. 111, 1077\u20131086. https:\/\/doi.org\/10.1007\/s00392-021-01971-3 (2022).","journal-title":"Clin. Res. Cardiol."},{"key":"87512_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cid\/ciac777","volume":"76","author":"P Danneels","year":"2023","unstructured":"Danneels, P. et al. Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse. Clin. Infect. Dis. 76, 281\u2013290. https:\/\/doi.org\/10.1093\/cid\/ciac777 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"87512_CR22","doi-asserted-by":"publisher","first-page":"18574","DOI":"10.1074\/jbc.RA118.006052","volume":"293","author":"TM Moon","year":"2018","unstructured":"Moon, T. M. et al. The structures of penicillin-binding protein 4 (PBP4) and PBP5 from Enterococci provide structural insights into \u03b2-lactam resistance. J. Biol. Chem. 293, 18574\u201318584. https:\/\/doi.org\/10.1074\/jbc.RA118.006052 (2018).","journal-title":"J. Biol. Chem."},{"key":"87512_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1128\/JB.186.5.1221-1228.2004","volume":"186","author":"A Arbeloa","year":"2004","unstructured":"Arbeloa, A. et al. Role of class A penicillin-binding proteins in PBP5-Mediated \u03b2-Lactam Resistance in Enterococcus faecalis. J. Bacteriol. 186, 1221\u20131228. https:\/\/doi.org\/10.1128\/JB.186.5.1221-1228.2004 (2004).","journal-title":"J. Bacteriol."},{"key":"87512_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","volume":"32","author":"E Sauvage","year":"2008","unstructured":"Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A. & Charlier, P. The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32, 234\u2013258. https:\/\/doi.org\/10.1111\/j.1574-6976.2008.00105.x (2008).","journal-title":"FEMS Microbiol. Rev."},{"key":"87512_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/mdr.2016.0030","volume":"23","author":"S D\u2019Arezzo","year":"2017","unstructured":"D\u2019Arezzo, S. et al. Ceftaroline Plus Ampicillin against Gram-positive organisms: results from E-Test synergy assays. Microb. Drug Resist. 23, 507\u2013515. https:\/\/doi.org\/10.1089\/mdr.2016.0030 (2017).","journal-title":"Microb. Drug Resist."},{"key":"87512_CR26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/jac\/dkg360","volume":"52","author":"J Gavalda","year":"2003","unstructured":"Gavalda, J. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J. Antimicrob. Chemother. 52, 514\u2013517. https:\/\/doi.org\/10.1093\/jac\/dkg360 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"87512_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/287070a0","volume":"287","author":"R Fontana","year":"1980","unstructured":"Fontana, R., Canepari, P., Satta, G. & Coyette, J. Identification of the lethal target of benzylpenicillin in Streptococcus faecalis by in vivo penicillin binding studies. Nature 287, 70\u201372. https:\/\/doi.org\/10.1038\/287070a0 (1980).","journal-title":"Nature"},{"key":"87512_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1099\/00221287-132-3-625","volume":"132","author":"P Canepari","year":"1986","unstructured":"Canepari, P., Lleo, M. D. M., Cornaglia, G., Fontana, R. & Satta, G. In Streptococcus faecium penicillin-binding protein 5 alone is sufficient for growth at Sub-maximal but not at maximal rate. Microbiology (N Y). 132, 625\u2013631. https:\/\/doi.org\/10.1099\/00221287-132-3-625 (1986).","journal-title":"Microbiol. (N Y)"},{"key":"87512_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1128\/AAC.00983-09","volume":"54","author":"X Henry","year":"2010","unstructured":"Henry, X., Amoroso, A., Coyette, J. & Joris, B. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob. Agents Chemother. 54, 953\u2013955. https:\/\/doi.org\/10.1128\/AAC.00983-09 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae032","author":"KJ Westbrook","year":"2024","unstructured":"Westbrook, K. J. et al. Differential in vitro susceptibility to ampicillin\/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates. J. Antimicrob. Chemother. https:\/\/doi.org\/10.1093\/jac\/dkae032 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"87512_CR31","doi-asserted-by":"publisher","unstructured":"Lazzaro, L. M., Cassisi, M., Stefani, S. & Campanile, F. Impact of PBP4 alterations on \u03b2-Lactam Resistance and Ceftobiprole Non-susceptibility among Enterococcus faecalis clinical isolates. Front. Cell. Infect. Microbiol. 11. https:\/\/doi.org\/10.3389\/fcimb.2021.816657 (2022).","DOI":"10.3389\/fcimb.2021.816657"},{"key":"87512_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jac\/dku386","volume":"70","author":"BJ Werth","year":"2015","unstructured":"Werth, B. J. et al. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. J. Antimicrob. Chemother. 70, 489\u2013493. https:\/\/doi.org\/10.1093\/jac\/dku386 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"87512_CR33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1128\/AAC.00131-07","volume":"51","author":"CA Arias","year":"2007","unstructured":"Arias, C. A., Singh, K. V., Panesso, D. & Murray, B. E. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and Vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51, 2043\u20132047. https:\/\/doi.org\/10.1128\/AAC.00131-07 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2018.07.015","volume":"93","author":"F Campanile","year":"2019","unstructured":"Campanile, F., Bongiorno, D., Mongelli, G., Zangh\u00ec, G. & Stefani, S. Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates. Diagn. Microbiol. Infect. Dis. 93, 77\u201381. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.07.015 (2019).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"87512_CR35","doi-asserted-by":"publisher","first-page":"e0355221","DOI":"10.1128\/mbio.03552-21","volume":"13","author":"F Rajer","year":"2022","unstructured":"Rajer, F. & Sandegren, L. The role of antibiotic resistance genes in the fitness cost of multiresistance plasmids. MBio 13, e0355221. https:\/\/doi.org\/10.1128\/mbio.03552-21 (2022).","journal-title":"MBio"},{"key":"87512_CR36","doi-asserted-by":"publisher","unstructured":"Levin, B. R. et al. Theoretical Considerations and Empirical Predictions of the Pharmaco- and Population Dynamics of Heteroresistance. BioRxiv. (2023). https:\/\/doi.org\/10.1101\/2023.09.21.558832","DOI":"10.1101\/2023.09.21.558832"},{"key":"87512_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrmicro1146","volume":"3","author":"A Vendeville","year":"2005","unstructured":"Vendeville, A., Winzer, K., Heurlier, K., Tang, C. M. & Hardie, K. R. Making sense of metabolism: Autoinducer-2, LUXS and pathogenic bacteria. Nat. Rev. Microbiol. 3, 383\u2013396. https:\/\/doi.org\/10.1038\/nrmicro1146 (2005).","journal-title":"Nat. Rev. Microbiol."},{"key":"87512_CR38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S1473-3099(02)00447-4","volume":"2","author":"M C\u00e1mara","year":"2002","unstructured":"C\u00e1mara, M., Williams, P. & Hardman, A. Controlling infection by tuning in and turning down the volume of bacterial small-talk. Lancet Infect. Dis. 2, 667\u2013676. https:\/\/doi.org\/10.1016\/S1473-3099(02)00447-4 (2002).","journal-title":"Lancet Infect. Dis."},{"key":"87512_CR39","doi-asserted-by":"publisher","unstructured":"Swift, S. et al. Quorum sensing as a population-density-dependent determinant of bacterial physiology, pp. 199\u2013270 (2001). https:\/\/doi.org\/10.1016\/S0065-2911(01)45005-3","DOI":"10.1016\/S0065-2911(01)45005-3"},{"key":"87512_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12964-023-01154-9","volume":"21","author":"NG Naga","year":"2023","unstructured":"Naga, N. G., El-Badan, D. E., Ghanem, K. M. & Shaaban, M. I. It is the time for quorum sensing inhibition as alternative strategy of antimicrobial therapy. Cell. Commun. Signal. 21, 133. https:\/\/doi.org\/10.1186\/s12964-023-01154-9 (2023).","journal-title":"Cell. Commun. Signal."},{"key":"87512_CR41","doi-asserted-by":"publisher","unstructured":"Sionov, R. V. & Steinberg, D. Targeting the holy triangle of quorum sensing, biofilm formation, and antibiotic resistance in pathogenic bacteria. Microorganisms. 10 (2022). https:\/\/doi.org\/10.3390\/microorganisms10061239","DOI":"10.3390\/microorganisms10061239"},{"key":"87512_CR42","doi-asserted-by":"publisher","unstructured":"Lu, Y. et al. Quorum sensing regulates heteroresistance in Pseudomonas aeruginosa. Front. Microbiol. 13 (2022). https:\/\/doi.org\/10.3389\/fmicb.2022.1017707.","DOI":"10.3389\/fmicb.2022.1017707"},{"key":"87512_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/1040841X.2020.1863329","volume":"47","author":"SP Lopes","year":"2021","unstructured":"Lopes, S. P., Jorge, P., Sousa, A. M. & Pereira, M. O. Discerning the role of polymicrobial biofilms in the ascent, prevalence, and extent of heteroresistance in clinical practice. Crit. Rev. Microbiol. 47, 162\u2013191. https:\/\/doi.org\/10.1080\/1040841X.2020.1863329 (2021).","journal-title":"Crit. Rev. Microbiol."},{"key":"87512_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/microorganisms8030425","volume":"8","author":"X Zhao","year":"2020","unstructured":"Zhao, X., Yu, Z. & Ding, T. Quorum-sensing regulation of Antimicrobial Resistance in Bacteria. Microorganisms 8, 425. https:\/\/doi.org\/10.3390\/microorganisms8030425 (2020).","journal-title":"Microorganisms"},{"key":"87512_CR45","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/AAC.00296-10","volume":"54","author":"B Moy\u00e1","year":"2010","unstructured":"Moy\u00e1, B., Zamorano, L., Juan, C., Ge, Y. & Oliver, A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54, 3933\u20133937. https:\/\/doi.org\/10.1128\/AAC.00296-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR46","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1128\/AAC.01230-07","volume":"52","author":"ME Skindersoe","year":"2008","unstructured":"Skindersoe, M. E. et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 3648\u20133663. https:\/\/doi.org\/10.1128\/AAC.01230-07 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"87512_CR47","doi-asserted-by":"publisher","first-page":"e0131322","DOI":"10.1128\/aac.01313-22","volume":"67","author":"C Tascini","year":"2023","unstructured":"Tascini, C. et al. Infective Endocarditis Associated with Implantable Cardiac device by Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa, successfully treated with Source Control and Cefiderocol Plus Imipenem. Antimicrob. Agents Chemother. 67, e0131322. https:\/\/doi.org\/10.1128\/aac.01313-22 (2023).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87512-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T23:22:40Z","timestamp":1738106560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87512-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87512"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87512-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board, Department of Medicine, University of Udine. Prot IRB: 111\/2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective and observational nature of the analysis, patient\u2019s signed written informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Due to the retrospective and observational nature of the analysis, patient\u2019s signed written informed consent to publish was waived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"3519"}}